8 results on '"Cinzia Maugeri"'
Search Results
2. T-Cell Lymphocyte Kinetics As a Predictive Biomarker of Blinatumomab MRD Response in ALL-B Patients: A Single-Center Prospective Study
- Author
-
Uros Markovic, Andrea Duminuco, Nunziatina Laura Parrinello, Luca Lo Nigro, Elisa Mauro, Calogero Vetro, Marina Parisi, Cinzia Maugeri, Giuseppe Milone, Alessandra Romano, Francesco Di Raimondo, and Salvatore Leotta
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
3. Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases
- Author
-
Andrea Duminuco, Calogero Vetro, Cinzia Maugeri, Elisa Mauro, Giuseppe A. M. Palumbo, Marina S. Parisi, Benedetta Esposito, Giuseppe Giuliano, Alessandra Romano, and Francesco Di Raimondo
- Subjects
Saprochaete capitata ,hemic and lymphatic diseases ,emergent and multiresistant micro-organisms ,immunocompromised patients ,voriconazole ,hematological malignancies ,Hematology - Abstract
Infections occurring in immunocompromised patients after intensive chemotherapy are often difficult to eradicate and are capable of even being fatal. New emergent and dangerous drug-resistant micro-organisms are likely to appear in these specific scenarios. Clinical features mainly include progressive pneumonia, bacteriemia/fungemia, or extrapulmonary dissemination among infections. The treatment of these microorganisms is still an open challenge since there is a lack of clear treatment guidelines. Indeed, infections from these microorganisms can lead to a rapidly fatal clinical course in immunocompromised patients, especially those who have acute leukemia. We describe the case of a young patient with acute myeloid leukemia who contracted an infection from Saprochaete capitata during post-chemotherapy aplasia.
- Published
- 2022
4. Therapeutic innovation for multi-resistant candidemics: synergy of isavuconazole and caspofungin association
- Author
-
Andrea Duminuco, Marina Parisi, Francesco Di Raimondo, Bruno Garibaldi, Elisa Mauro, Calogero Vetro, Cinzia Maugeri, and Giuseppe A. Palumbo
- Subjects
Oncology ,Fungal infection ,medicine.medical_specialty ,business.industry ,isavuconazole ,Case Report ,Hematology ,macromolecular substances ,Resistant tuberculosis ,chemistry.chemical_compound ,chemistry ,Internal medicine ,combined antifungal therapy ,hematological patients ,medicine ,Diseases of the blood and blood-forming organs ,Caspofungin ,caspofungin ,RC633-647.5 ,business ,Candida - Abstract
Fungal infections occurring in immunocompromised patients after immuno-chemotherapy treatment, are often difficult to eradicate and capable of even being fatal. Systemic mycoses affecting severely immunocompromised patients often manifest acutely with rapidly progressive pneumonia, fungemia, or manifestations of extrapulmonary dissemination. Opportunistic fungal infections (mycoses) include several pathogens elements, as Candidiasis, Aspergillosis, Mucormycosis (zygomycosis) and Fusariosis. Prompt diagnosis and effective therapy are needed to improve the associated morbidity and mortality, especially in cases with non-canonical fungal localizations and not responsive to the available antifungal drugs.
- Published
- 2021
5. Preliminary Results of a Prospective Observational Study to Assess the Prevalence of Gaucher Disease in an Adult Population Affected By MGUS
- Author
-
Giuseppe Longo, Caterina Musolino, Concetta Conticello, Vanessa Innao, Daniela Nicolosi, Cinzia Maugeri, Ugo Consoli, Francesco Di Raimondo, Maria Rocca Cingari, Flavia Fiorenza, Valeria Calafiore, Gaetano Giuffrida, and Alessandra Romano
- Subjects
glucosidase ,Pediatrics ,medicine.medical_specialty ,enzymes ,Immunology ,Gaucher disease ,Disease ,Compound heterozygosity ,metabolic diseases ,Biochemistry ,Internal medicine ,Medicine ,glucosylceramidase ,lysosomal storage diseases ,observational studies ,Hematology ,Gaucher disease, monoclonal gammopathy of undetermined significance, observational studies, glucosidase, blood spot specimen, enzymes, genetic disorder, glucosylceramidase, lysosomal storage diseases, metabolic diseases ,business.industry ,Genetic disorder ,Cell Biology ,medicine.disease ,Institutional review board ,Monoclonal ,genetic disorder ,blood spot specimen ,business ,Glucocerebrosidase ,Monoclonal gammopathy of undetermined significance ,monoclonal gammopathy of undetermined significance - Abstract
INTRODUCTION: Gaucher disease (GD) is a rare, autosomal recessive genetic disorder. It is due to a deficiency of the lysosomal enzyme, glucocerebrosidase, which leads to an accumulation of its substrate, glucosylceramide, in tissue macrophage with damage to hematological, visceral, and skeletal organ systems. Although GD has a continuous spectrum of severity, it is traditionally classified into three forms: type 1 (chronic; lacking early onset neuronopathy), type 2 (acute; with early onset neuronopathy),and type 3 (chronic; with early onsetneuronopathy). Type 1GD accounts for more than 90% all GD patients. Its prevalence world-wide is 1 in 50,000-100,000 but it is as high as ~1 in 850 in individuals of Ashkenazi heritage. Type 1 GD is frequently associated to monoclonal gammopathies; despite the emergence of theories advanced to explain these observations, the cause remains unknown. OBJECTIVE: Aim of the ongoing observational study is to determine the prevalence of unrecognized type I GD in a selected Italian population with MGUS. MATERIALS AND METHODS: From January 2018, dried blood spots (DBS) sample from patients with laboratory evidence of MGUS coming from five hematology units of Sicily and Calabria were collected and tested for the acid β-glucosidase enzyme activity. The study was approved by the local institutional review board. All patients provided informed consent for the prospective collection of their data. In case of DBS positive result, a confirmatory test was carried over and, if GD was confirmed, the patient was referred to one of the Regional Reference Centers for Metabolic Disease, as for current clinical practice in Italy. RESULTS: To date, 308 patients with MGUS were enrolled; acid β-glucosidase enzyme activity was low in 22 patients (7%). Sequence analysis of GBA gene was performed in these selected patients, but we have found only 4 patients with heterozygous mutation in the GBA1 gene, 1 homozygous(c.1226A>G -N370S) and 1 compound heterozygous (c.1226A>G -N370S and c.1448T>C -L444P); the last 2 patients had signs of GD (hepato-splenomegaly and mild thrombocytopenia). CONCLUSIONS: Type 1 GD remains a rare lysosomal storage disorder but preliminary results of our observational study show that it should be considered in the diagnostic framework of patients with MGUS, particularly when other GD symptoms are present. Disclosures Conticello: Celgene: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding. Di Raimondo:Celgene: Consultancy, Honoraria, Research Funding; Takeda: Consultancy; Amgen: Consultancy, Honoraria, Research Funding.
- Published
- 2019
6. Impact of Cumulative Dose of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real Life Survey of the Sicilian Myeloma Network
- Author
-
Giuseppe Longo, Vanessa Innao, Emilia Cotzia, Valeria Calafiore, Stefania Tringali, Donato Mannina, Enrica Antonia Martino, Maurizio Musso, Bruno Garibaldi, Ugo Consoli, Vittorio Del Fabro, Salvatore Innorcia, Clotilde Cangialosi, Concetta Conticello, Cinzia Maugeri, Marina Parisi, Alessandra Romano, Melania Carlisi, Massimo Poidomani, Giuseppe Sapienza, and Francesco Di Raimondo
- Subjects
medicine.medical_specialty ,congenital, hereditary, and neonatal diseases and abnormalities ,complete remission ,Immunology ,lenalidomide ,adverse event ,Context (language use) ,dexamethasone ,Biochemistry ,chemistry.chemical_compound ,Median follow-up ,Internal medicine ,medicine ,carfilzomib, dexamethasone, lenalidomide, multiple myeloma, toxic effect, adverse event, bortezomib, complete remission, erythropoietin, febrile neutropenia ,Multiple myeloma ,Lenalidomide ,toxic effect ,carfilzomib ,business.industry ,Cumulative dose ,bortezomib ,Cell Biology ,Hematology ,medicine.disease ,Carfilzomib ,multiple myeloma ,Regimen ,febrile neutropenia ,chemistry ,erythropoietin ,business ,Febrile neutropenia ,medicine.drug - Abstract
Background: Triplet-based lenalidomide plus dexamethasone (Rd) combinations have become the new standard of care for early relapse and refractory multiple myeloma (RRMM). Carfilzomib is a novel selective proteasome inhibitor (PI) with high efficacy in RRMM. The ASPIRE phase 3 trial showed the superiority of carfilzomib-based triplet (KRd compared to Rd), leading to approval of K for RRMM. However, little is known about safety and efficacy of KRd outside a clinical trial context. Experimental design and aims: In 11 Sicilian Centers belonging to the Sicilian Myeloma Network, from November 2016, when KRd regimen was approved in Italy, to June 2018, 103 consecutive RRMM patients (previous lines 1-10) have received KRd regimen, according to ASPIRE schedule. Lenalidomide dosage was reduced in patients with a low count of platelet and/or renal failure according to manufacturer guidelines. Since previous studies have demonstrated that increased cumulative dose of first generation PI bortezomib significantly improved overall survival of patients treated with VMP regimen, we studied the effect of cumulative dose of Carfilzomib in RRMM patients receiving KRd. Results: Clinical and demographic characteristics of patients included in the study are summarized in Table 1. Median age was 65 years (range 33-86), most patients were males (54%). About half of the patients included in the survey were refractory to previous treatment (54%); Sixty-five (63%) patients received at least 5 cycles of KRd and 38 (36%) received at least 10 cycles. Overall response rate was 34% (35 patients); 18 patients (17%) achieved a complete response (CR), 6 patients minimal response (MR), 13 (12%) patients achieved PR, 16 patients achieved MR and then progressed; progression occurred in 20 patients, among them 3 did not reached any response. Delays due to adverse events were 33%, mainly due to febrile neutropenia (22%), thromboembolic events (4.5%), heart failure (3%), or thrombocytopenia (4.5%). To prevent hematological toxicities, 24% of patients received granulocyte growth factors, 15% erythropoietin. In 30 patients treatment was reduced (mainly due to lenalidomide toxicity) and in 5 patients discontinued for toxicity. Thus, median cumulative carfizomib doses at 2, 3, 4 and 6 cycles were respectively 480 mg (282 mg/m2), 735 mg (435 mg/m2), 995 mg (589 mg/m2) and 1522mg (890 mg/m2). After a median follow up of 16.2 months, PFS at 12 months was 67.3%. We found that median PFS was significantly longer in patients who received at least 480 mg (282 mg/m2) within first two months of treatment compared to those that could not receive full-dose KRd (respectively, undefined vs 11 months p=0.04). To identify patients that could obtain the most advantage by KRd treatment, 65 patients who had received at least six cycles were distinguished in two groups, based on previous treatments. In group A, 27 patients were heavily pretreated (median previous lines 4, range 2-10) and had previously received lenalidomide while 38 patients included in group B were less pretreated (median previous lines 3, range 1-5) and lenalidomide- naïve. We found that group A had lower PFS than group B although duration of PFS from the previous treatment was similar in both groups. Conclusions: In our cohort of patients rate of VGPR or better obtained with KRd combination was high with an overall response rate of 34%, with an acceptable safety profile. It is therefore reasonable that approaches to achieve a higher cumulative dose, such as continuing therapy in responding patients and/or proactive adverse events management, influence efficacy. In addition, it is likely that patients not previously exposed to several lines of treatment including lenalidomide are the best candidate for a favorable outcome with KRd regimen. Disclosures Di Raimondo: Celgene: Honoraria; Takeda: Honoraria, Research Funding.
- Published
- 2018
7. PB2123 FEASIBILITY, TOLERABILITY AND EFFICACY OF CARFILZOMIB, LENALIDOMIDE AND DESAMETHASONE(KRD) IN RELAPSED REFRACTORY MYELOMA PATIENTS: A REAL-LIFE SURVEY OF THE SICILIAN MYELOMA NETWORK
- Author
-
Santo Neri, Renato Scalone, V. Del Fabro, Cinzia Maugeri, Bruno Garibaldi, Ugo Consoli, Giuseppe Mineo, Maurizio Musso, Melania Carlisi, Uros Markovic, Marina Parisi, F. Di Raimondo, Emilia Cotzia, Anxur Merenda, Salvatore Leotta, A. Romano, Valerio Leotta, C. Conticello, Giuseppe Longo, Clotilde Cangialosi, Vanessa Innao, Donato Mannina, Enrica Antonia Martino, Valeria Calafiore, Massimo Poidomani, and Giuseppe Sapienza
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Hematology ,Carfilzomib ,chemistry.chemical_compound ,Tolerability ,chemistry ,Internal medicine ,Relapsed refractory ,medicine ,Desamethasone ,business ,Lenalidomide ,medicine.drug - Published
- 2019
8. The Combined Evaluation of Neutrophil, T-Lymphocyte and Monocyte Counts Provides New Prognostic Information in CLL Patients
- Author
-
Cinzia Maugeri, Giovanna Motta, Anna Triolo, Annalisa Chiarenza, Giuseppina Rizzo, Alessandra Romano, Angelo Curto Pelle, Francesco Di Raimondo, Cesarina Giallongo, Piera La Cava, Nunziatina Laura Parrinello, Mary Ann Di Giorgio, Daniele Tibullo, Valerio Leotta, L Caruso, and Amalia Figuera
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Monocyte ,Immunology ,Cancer ,Cell Biology ,Hematology ,CD38 ,medicine.disease ,Biochemistry ,Asymptomatic ,medicine.anatomical_structure ,B symptoms ,Tumor progression ,Internal medicine ,medicine ,Absolute neutrophil count ,Neutrophil to lymphocyte ratio ,medicine.symptom ,business - Abstract
The recent advances in cytogenetic and molecular diagnostic techniques has provided a better understanding of biology of CLL and a better prediction of disease progression and refractoriness but they are not easily accessible to all Institutions. CLL cells depend on microenvironmental interactions for proliferation and survival that are at least partially mediated through B cell receptor (BCR) signaling. An increased number of studies describe the emerging role of neutrophils and monocytes as mediators of the inflammation process and antitumor immunity modulation that support tumorigenesis and tumor progression. The neutrophil to lymphocyte ratio (NLR), has been recently published as new marker of systemic inflammation associated with outcome in different cancer types. In our study we retrospectively evaluated the prognostic significance of peripheral blood neutrophils, monocytes and non-neoplastic lymphocytes in a unicentric, unselected, CLL cohort of 400 CLL patients (160 were treated). The study was approved by the institutional board review;informed consent was obtained from patients. Using the blood count and the Flow cytometric analysis reports, peripheral blood absolute neutrophil count (ANC), absolute monocyte count (AMC) and absolute T-lymphocyte count (ALC-CD3+) were evaluated and the neutrophil to T-lymphocyte ratio (NLR), the monocyte to T-lymphocyte ratio (MLR) and the neutrophil to monocyte ratio (NMR) were calculated. Clinical and biological data from all patients were also retrieved. Serial count and ratio were evaluated at diagnosis, during follow up and at relapse to make a better comparison with the major clinical and prognostic markers commonly used. The median ratio for NLR 2.67 and patients with pre-treatment NLR > 3 had a shorter time from diagnosis to treatment initiation. CLL patients showed an increase in the absolute number of monocytes compared to normal controls (788±65 cells/μL vs 469±51 cells/μL, p=0.005) and MLR appeared higher in advanced stage (stage Binet C) and bulky disease (p=0.06). High level of both NLR and MLR (cut off >3) correlated with the presence of a complex karyotype detected by FISH (p=0.03, p=0.016). NLR ratio was associated with the absence of serum prognostic markers, such as the expression of CD38, ZAP-70 and CD49d. This result, apparently conflicting, could strengthen the NLR as an independent prognostic factor. NMR was higher in asymptomatic patients (absence vs. presence of B symptoms, p=0.02) and this data resulted independent from disease stage. NMR median value was significantly higher in untreated patients than in patients who received treatment (p=0.01), strengthening the hypothesis that this ratio is associated with a more indolent form of disease. In this contest, the subset of patients with CD49d positive disease showed the lowest NMR value. This data seems of relevance, being CD49d a recently discovered and validated prognostic marker. ANC/ALC and AMC/ALC ratio significantly increased at relapse compare to baseline (NLR average onset 2.3±0.4 vs 3.4±0.6 at relapse). The median NMR value showed conversely the opposite trend: NMR is reduced in first relapse (NMR average onset 7.2±0.4 vs. 5.4±0.5 at relapse). These combined ratios reflect both the inflammatory status, the immune response and the microenviromental network that contribute to aggressive tumor biology and disease progression. They are simple, cheap, easily measured and reproducible and can be integrated into daily clinical practice as new prognostic markers for CLL. Disclosures Chiarenza: Gilead: Consultancy; Janssen: Consultancy; Roche: Consultancy.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.